New Drugs of 2012, Part 2

Michael A. Mancano, PharmD
Published Online: Tuesday, March 19, 2013
Follow Pharmacy_Times:
New Drugs of 2012, Part 2

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University School of Pharmacy
Philadelphia, Pennsylvania
 
Clinical Consultant, Pennsylvania Hospital
Department of Pharmacy
Philadelphia, Pennsylvania



Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.
 
Faculty
Michael A. Mancano, PharmD
 
Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA; and Elena Beyzarov, PharmD
 
Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas
 
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Educational Objectives
 
Upon completion of this educational activity, participants should be able to:
  1. Discuss the clinical indications of the new drugs approved by the FDA in 2012.
  2. Explain the various mechanisms of action of the drugs discussed within this activity.
  3. Recognize the clinically relevant drug interactions and adverse reactions for the drugs reviewed in this activity.
  4. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.
Target audience:  Pharmacists
Type of activity:  Knowledge
Release date:  March 10, 2013
Expiration date:  March 10, 2015
Estimated time to complete activity:  2 hours
Fee:  This lesson is free online

Click here to view this activity.


Related Articles
The prices for brand-name prescription medications commonly used by older adults increased by an approximate average of 13% last year, more than 8 times faster than the general inflation rate.
Latest Issues
$auto_registration$